Exelixis Inc.

10/15/2024 | Press release | Distributed by Public on 10/15/2024 14:16

Material Event Form 8 K

Item 8.01. Other Events.
On October 15, 2024, Exelixis, Inc. (Exelixis) announced that the U.S. District Court for the District of Delaware (the Delaware District Court) issued a ruling in our two consolidated patent lawsuits against MSN Pharmaceuticals, Inc. (individually and collectively with certain of its affiliates, including MSN Laboratories Private Limited, referred to as MSN), rejecting MSN's invalidity challenge to each of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015, which expire January 15, 2030, and had previously entered a stipulation that MSN's proposed Abbreviated New Drug Application (ANDA) product infringes these patents. The Delaware District Court also ruled that Exelixis' U.S. Patent No. 11,298,349 is not invalid and that MSN's proposed ANDA product does not infringe this patent, which expires February 10, 2032. The Delaware District Court also requested the parties jointly submit a final judgment reflecting the opinion by October 22, 2024. Based on the Delaware District Court's opinion, the effective date of any final approval by the U.S. Food and Drug Administration of MSN's ANDA shall not be a date earlier than January 15, 2030, the expiration date of each of U.S. Patents No. 11,091,439, 11,091,440 and 11,098,015.
This Current Report on Form 8-K contains forward-looking statements, including, without limitation, statements related to the potential timing for MSN to commercially launch its proposed generic product in the U.S. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include factors detailed from time to time under the caption "Risk Factors" in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' other future filings with the Securities and Exchange Commission. Exelixis undertakes no duty to update these statements other than to the extent required by applicable law.